Showing results (181-190 of 193) with videos related to

Sort By:
Pageof 20
Journal of Cancer|November 19, 2019
The impact of Adult Comorbidity Evaluation-27 on the clinical outcome of elderly nasopharyngeal carcinoma patients treated with chemoradiotherapy or radiotherapy: a matched cohort analysisYue-Feng Wen, Xue-Song Sun, Li Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2022
Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority TrialXiao-Yun Li, Dong-Hua Luo, Ling Guo, et al.
JAMA Oncology|June 18, 2025
Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical TrialShan-Shan Guo, Xiao-Yun Li, Li-Ting Liu, et al.
Nature Communications|March 31, 2026
Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trialLi-Ting Liu, Xue-Song Sun, Ting-Ting Quan, et al.
The Lancet. Oncology|June 8, 2023
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trialLi-Ting Liu, Huai Liu, Ying Huang, et al.
The Lancet. Oncology|November 10, 2024
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trialSai-Lan Liu, Xiao-Yun Li, Jin-Hao Yang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2025
[<sup>18</sup>F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinomaLi-Ting Liu, Zhen-Chong Yang, Jia-Rui He, et al.
Eclinicalmedicine|November 17, 2025
Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trialYu-Chen Li, Xiao-Yun Li, Kai-Qi Lan, et al.
Journal of the National Cancer Institute|October 16, 2015
Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal CarcinomaLin-Quan Tang, Chao-Feng Li, Jing Li, et al.
BMC Medicine|November 28, 2023
Radiomic signatures reveal multiscale intratumor heterogeneity associated with tissue tolerance and survival in re-irradiated nasopharyngeal carcinoma: a multicenter studyTing Liu, Di Dong, Xun Zhao, et al.
Pageof 20